ESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX

Core Viewpoint - A class action securities lawsuit has been filed against ESSA Pharma Inc. due to alleged securities fraud affecting investors between December 12, 2023, and October 31, 2024 [1] Group 1: Lawsuit Details - The complaint alleges that ESSA Pharma Inc. made false statements regarding the efficacy of masofaniten in combination with enzalutamide, claiming it had no clear efficacy benefit over enzalutamide alone [2] - It is claimed that masofaniten was less effective in treating prostate cancer than previously communicated to investors [2] - The M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, contradicting the company's public statements [2] - Defendants allegedly overstated masofaniten's clinical, regulatory, and commercial prospects, leading to materially false and misleading public statements [2] Group 2: Next Steps for Investors - Investors who suffered losses in ESSA Pharma Inc. during the relevant timeframe have until March 25, 2025, to request appointment as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4]